Australian biotechnology company Vaxxas exclusively licensed its Nanopatch to pharma giant Merck for the commercialization of an undisclosed vaccine candidate. Although the financial details of the agreement are undisclosed, it...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)